Search

Author/Creator Paprcka, S.

1. AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics. (October 2022)

Authors:
Paprcka, S.; Sridhar, S.; Goshayeshi, A.; Park, E.; Liu, S.; Flores, R.; Rocha, L.; Miles, D.; Lamani, M.; Cho, S.; Wang, N.; Guan, Y.; Chandrasekar, S.; Kushwaha, R.; Jafri, S.; Kaplan, A.; Stagnaro, E.; Seitz, L.; Kline, J.; Fernandez-Salas, E.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S110
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801. (October 2022)

Authors:
Miles, D.; Paprcka, S.; Foley, C.; Qu, S.; Lamani, M.; Paladugu, S.; Huang, H.T.; Tibrewal, N.; Chen, A.; Kulusich, J.; Garrido-Shaqfeh, S.; Fabila, P.; Sridhar, S.; Liu, S.; Swinarski, D.; Zhao, X.; Fernandez-Salas, E.; Green, D.; Jin, L.; Leleti, M.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search